L-type Ca2+ Channel Blockers Promote Ca2+ Accumulation when Dopamine Receptors Are Activated in Striatal Neurons

Overview

Journal Brain Res Mol Brain Res

Specialties Molecular Biology
Neurology

Date 2004 Nov 9

PMID 15530653

Citations 5

Authors

Molly E Eaton

Wendy Macias

Rachael M Youngs

Anjali Rajadhyaksha

Joshua T Dudman

Christine Konradi

Affiliations

Soon will be listed here.

Abstract

Dopamine (DA) receptor-mediated signal transduction and gene expression play a central role in many brain disorders from schizophrenia to Parkinson's disease to addiction. While trying to evaluate the role of L-type Ca2+ channels in dopamine D1 receptor-mediated phosphorylation of the transcription factor cyclic AMP response element-binding protein (CREB), we found that activation of dopamine D1 receptors alters the properties of L-type Ca2+ channel inhibitors and turns them into facilitators of Ca2+ influx. In D1 receptor-stimulated neurons, L-type Ca2+ channel blockers promote cytosolic Ca2+ accumulation. This leads to the activation of a molecular signal transduction pathway and CREB phosphorylation. In the absence of dopamine receptor stimulation, L-type Ca2+ channel blockers inhibit CREB phosphorylation. The effect of dopamine on L-type Ca2+ channel blockers is dependent on protein kinase A (PKA), suggesting that protein phosphorylation plays a role in this phenomenon. Because of the adverse effect of activated dopamine receptors on L-type Ca2+ channel blocker action, the role of L-type Ca2+ channels in the dopamine D1 receptor signal transduction pathway cannot be assessed with pharmacological tools. However, with antisense technology, we demonstrate that L-type Ca2+ channels contribute to D1 receptor-mediated CREB phosphorylation. We conclude that the D1 receptor signal transduction pathway depends on L-type Ca2+ channels to mediate CREB phosphorylation.

Citing Articles

Therapeutic Potential of Heterocyclic Compounds Targeting Mitochondrial Calcium Homeostasis and Signaling in Alzheimer's Disease and Parkinson's Disease.

Tapias V, Gonzalez-Andres P, Pena L, Barbero A, Nunez L, Villalobos C Antioxidants (Basel). 2023; 12(6).

PMID: 37372013 PMC: 10294814. DOI: 10.3390/antiox12061282.

Coherent and Contradictory Facts, Feats and Fictions Associated with Metal Accumulation in Parkinson's Disease: Epicenter or Outcome, Yet a Demigod Question.

Rasheed M, Tripathi S, Mishra S, Singh M Mol Neurobiol. 2016; 54(6):4738-4755.

PMID: 27480264 DOI: 10.1007/s12035-016-0016-y.

Involvement of amygdalar protein kinase A, but not calcium/calmodulin-dependent protein kinase II, in the reconsolidation of cocaine-related contextual memories in rats.

Arguello A, Hodges M, Wells A, Lara 3rd H, Xie X, Fuchs R Psychopharmacology (Berl). 2013; 231(1):55-65.

PMID: 23873418 PMC: 3852194. DOI: 10.1007/s00213-013-3203-9.

Pharmacology of signaling induced by dopamine D(1)-like receptor activation.

Undieh A Pharmacol Ther. 2010; 128(1):37-60.

PMID: 20547182 PMC: 2939266. DOI: 10.1016/j.pharmthera.2010.05.003.

Mechanism of dopamine mediated inhibition of neuropeptide Y release from pheochromocytoma cells (PC12 cells).

Cao G, Gardner A, Westfall T Biochem Pharmacol. 2007; 73(9):1446-54.

PMID: 17286966 PMC: 2709075. DOI: 10.1016/j.bcp.2007.01.003.

References

Das S, Grunert M, Williams L, Vincent S . NMDA and D1 receptors regulate the phosphorylation of CREB and the induction of c-fos in striatal neurons in primary culture. Synapse. 1997; 25(3):227-33. DOI: 10.1002/(SICI)1098-2396(199703)25:3<227::AID-SYN1>3.0.CO;2-D. View

Brooks D . Dopamine agonists: their role in the treatment of Parkinson's disease. J Neurol Neurosurg Psychiatry. 2000; 68(6):685-9. PMC: 1736955. DOI: 10.1136/jnnp.68.6.685. View

Gray P, Scott J, Catterall W . Regulation of ion channels by cAMP-dependent protein kinase and A-kinase anchoring proteins. Curr Opin Neurobiol. 1998; 8(3):330-4. DOI: 10.1016/s0959-4388(98)80057-3. View

Carlezon Jr W, Thome J, OLSON V, Brodkin E, Hiroi N, Duman R . Regulation of cocaine reward by CREB. Science. 1998; 282(5397):2272-5. DOI: 10.1126/science.282.5397.2272. View

Konradi C, Leveque J, Hyman S . Amphetamine and dopamine-induced immediate early gene expression in striatal neurons depends on postsynaptic NMDA receptors and calcium. J Neurosci. 1996; 16(13):4231-9. PMC: 4203342. View

Cepeda C, BUCHWALD N, Levine M . Neuromodulatory actions of dopamine in the neostriatum are dependent upon the excitatory amino acid receptor subtypes activated. Proc Natl Acad Sci U S A. 1993; 90(20):9576-80. PMC: 47612. DOI: 10.1073/pnas.90.20.9576. View

Nestler E . Molecular basis of long-term plasticity underlying addiction. Nat Rev Neurosci. 2001; 2(2):119-28. DOI: 10.1038/35053570. View

Rajadhyaksha A, Barczak A, Macias W, Leveque J, Lewis S, Konradi C . L-Type Ca(2+) channels are essential for glutamate-mediated CREB phosphorylation and c-fos gene expression in striatal neurons. J Neurosci. 1999; 19(15):6348-59. PMC: 4204489. View

Sheng M, McFadden G, Greenberg M . Membrane depolarization and calcium induce c-fos transcription via phosphorylation of transcription factor CREB. Neuron. 1990; 4(4):571-82. DOI: 10.1016/0896-6273(90)90115-v. View

10.

Dudman J, Eaton M, Rajadhyaksha A, Macias W, Taher M, Barczak A . Dopamine D1 receptors mediate CREB phosphorylation via phosphorylation of the NMDA receptor at Ser897-NR1. J Neurochem. 2003; 87(4):922-34. PMC: 4203348. DOI: 10.1046/j.1471-4159.2003.02067.x. View

11.

Davis K, Kahn R, Ko G, Davidson M . Dopamine in schizophrenia: a review and reconceptualization. Am J Psychiatry. 1991; 148(11):1474-86. DOI: 10.1176/ajp.148.11.1474. View

12.

Konradi C, Cole R, Heckers S, Hyman S . Amphetamine regulates gene expression in rat striatum via transcription factor CREB. J Neurosci. 1994; 14(9):5623-34. PMC: 6577107. View

13.

Gonzalez G, Montminy M . Cyclic AMP stimulates somatostatin gene transcription by phosphorylation of CREB at serine 133. Cell. 1989; 59(4):675-80. DOI: 10.1016/0092-8674(89)90013-5. View

14.

Nestler E . Molecular neurobiology of addiction. Am J Addict. 2001; 10(3):201-17. DOI: 10.1080/105504901750532094. View

15.

Carlsson A . Treatment of Parkinson's with L-DOPA. The early discovery phase, and a comment on current problems. J Neural Transm (Vienna). 2002; 109(5-6):777-87. DOI: 10.1007/s007020200064. View

16.

Cepeda C, Colwell C, Itri J, Chandler S, Levine M . Dopaminergic modulation of NMDA-induced whole cell currents in neostriatal neurons in slices: contribution of calcium conductances. J Neurophysiol. 1998; 79(1):82-94. DOI: 10.1152/jn.1998.79.1.82. View

17.

Sassone-Corsi P, Visvader J, Ferland L, Mellon P, Verma I . Induction of proto-oncogene fos transcription through the adenylate cyclase pathway: characterization of a cAMP-responsive element. Genes Dev. 1988; 2(12A):1529-38. DOI: 10.1101/gad.2.12a.1529. View

18.

Hyman S, Cole R, Konradi C, Kosofsky B . Dopamine regulation of transcription factor-target interactions in rat striatum. Chem Senses. 1995; 20(2):257-60. DOI: 10.1093/chemse/20.2.257. View

19.

Sculptoreanu A, Scheuer T, Catterall W . Voltage-dependent potentiation of L-type Ca2+ channels due to phosphorylation by cAMP-dependent protein kinase. Nature. 1993; 364(6434):240-3. DOI: 10.1038/364240a0. View

20.

Hockerman G, Peterson B, Johnson B, Catterall W . Molecular determinants of drug binding and action on L-type calcium channels. Annu Rev Pharmacol Toxicol. 1997; 37:361-96. DOI: 10.1146/annurev.pharmtox.37.1.361. View